Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting
Werte in diesem Artikel
Oslo, January 6, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy-based voting rights without voting instructions for 8,020,964 shares, representing 23.31% of the total voting rights in the company.
The proxies are only valid for the Extraordinary General Meeting on January 9, 2025.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information, please see www.ultimovacs.com or contact:
Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355
Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632
Ausgewählte Hebelprodukte auf Ultimovacs AS Registered
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ultimovacs AS Registered
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu Ultimovacs AS Registered Shs
Analysen zu Ultimovacs AS Registered Shs
Keine Analysen gefunden.